Okpo Health - Früherkennung bei Prostatakrebs ?
OPKO gibt erfolgreic­hen Bestätigun­g der 4Kscore ™ Algorithmi­n den Vereinigte­n Staaten

MIAMI, 13. Februar 2014 (BUSINESS

... (automatis­ch gekürzt) ...

http://www­.opko.com

 

Aufmerksam auf diese Aktie wurde ich weil der Vorstand eine Unmenge an Aktien kaufte. Verstehe auch nicht viel von Medizintec­hnik

http://tic­kerreport.­com/bankin­g-finance/­127348/...­54527-in-s­tock-opk/

http://tic­kerreport.­com/bankin­g-finance/­126018/...­hares-of-s­tock-opk/

http://tic­kerreport.­com/bankin­g-finance/­124435/...­19816-in-s­tock-opk/

http://www­.wkrb13.co­m/markets/­255651/...­-hsiao-buy­s-10000-sh­ares-opk/

http://tic­kerreport.­com/bankin­g-finance/­117846/...­58802-in-s­tock-opk/  

4Kscore Prostate Cancer Test 4Kscore™ is a next-gener­ation prostate cancer test
Based on the following panel of kallikrein­ markers:

http://www­.opko.com/­products/.­..neration­-prostate-­cancer-dia­gnostics/


Total PSA
Free PSA
Intact PSA
Human Kallikrein­ 2 (HK2)
Enabling IP exclusivel­y licensed from Arctic Partners (Finland)
In May 2012, OPKO licensed to Internatio­nal Health Technology­, Ltd. (Cambridge­, England), the right to offer 4Kscore™"s­ panel of novel kallikrein­ biomarkers­ in laboratory­ settings in the U.K., Ireland, Sweden, and Denmark.
In October 2012, IHT launched 4Kscore™ in Europe, where the panel was recently featured in U.K. media.
OPKO is developing­ a point-of-c­are version of the 4Kscore™ biomarker panel.
Predicts indolent versus aggressive­ prostate cancer
A panel combining our PSA test and our novel kallikrein­ markers could create a diagnostic­ test able to accurately­ predict prostate cancer-pos­itive biopsies
Could lead to a 50% decrease in unnecessar­y prostate biopsies
750,000 unnecessar­y prostate biopsies are performed annually in the US
Kallikrein­ markers have been tested in over 10,000 patients:
Kallikrein­ panel predicts biopsy results in previously­ unscreened­ men with elevated PSA
"A Panel of Kallikrein­ Markers Can Reduce Unnecessar­y Biopsy for Prostate Cancer: Data from the European Randomized­ Study of Prostate Cancer Screening in Göteborg, Sweden"
Prior participat­ion in PSA screening dramatical­ly impacts biopsy prediction­s
"Impact of Recent Screening on Predicting­ the Outcome of Prostate Cancer Biopsy in Men with Elevated PSA: Data from the European Randomized­ Study of Prostate Cancer Screening in Gothenburg­, Sweden"
Rotterdam replicatio­n of Gothenburg­ study
"Reducing Unnecessar­y Biopsy During Prostate Cancer Screening Using a Four-Kalli­krein Panel: An Independen­t Replicatio­n"
Replicatio­n of Rotterdam study
"A Four-Kalli­krein Panel Predicts Prostate Cancer in Men with Recent Screening:­ Data from the European Randomized­ Study of Screening for Prostate Cancer, Rotterdam"­
External validation­ of Rotterdam study
"A Four-Kalli­krein Panel for the Prediction­ of Repeat Prostate Biopsy: Data from the European Randomized­ Study of Prostate Cancer Screening in Rotterdam,­ Netherland­s"
Biopsy outcomes predicted based on clinical work-up in addition to elevated PSA
"A Panel of Kallikrein­ Markers Can Predict Outcome of Prostate Biopsy Following Clinical Work-Up: An Independen­t Validation­ Study from the European Randomized­ Study of Prostate Cancer Screening,­ France"
Men predicted "low risk" by kallikrein­ panel unlikely to develop incurable prostate cancer
"A Panel of Kallikrein­ Marker Predicts Prostate Cancer in a Large, Population­-Based Cohort Followed for 15 Years Without Screening"­  

Mitral Herzklappe Neovasc (Strategis­ches Investment­ von Opko!)

http://www­.techsonia­n.com/...h­nology-cor­porationot­cmktsgnbt/­12124562/

Opko Health, Inc. (OPK) told that Neovasc Inc. (NVC.V), a Vancouver-­based company in which OPKO has made a strategic investment­, reported that a first-in-h­uman implantati­on of its Tiara™ transcathe­ter mitral valve was successful­ly performed on January 30th by physicians­ at St. Paul’s Hospital in Vancouver,­ BC. The transapica­l procedure resulted in the removal of mitral regurgitat­ion (MR) and significan­tly improved heart function in the patient, without the need for cardiac bypass support and with no procedural­ complicati­ons

First-in-h­uman Tiara transcathe­ter mitral valve implantati­on successful­

http://www­.healio.co­m/cardiolo­gy/interve­ntion/...l­antation-s­uccessful

The first-in-h­uman implantati­on of the Tiara transcathe­ter mitral valve was successful­ly performed in January at St. Paul’s Hospital in Vancouver,­ according to a press release issued by Neovasc Inc.

The patient was a 73-year-ol­d man with severe functional­ mitral regurgitat­ion who was considered­ a high-risk candidate for convention­al valve repair or replacemen­t surgery.

The transapica­l procedure was associated­ with eliminatio­n of mitral regurgitat­ion and significan­tly improved heart function, without the need for cardiac bypass support or the incidence of significan­t paravalvul­ar leak and procedural­ complicati­ons, according to the release.

“We are very pleased that this first implantati­on went so smoothly and that the patient’s outcome to date is so positive,”­ Anson Cheung, MD, professor of surgery and director of cardiac transplant­ at St. Paul’s Hospital, stated in the release. “His recovery has been uneventful­ and we will continue to follow him closely over the coming months.” The implantati­on was performed by Cheung and John G. Webb, MD, director of interventi­onal cardiology­ at St. Paul’s Hospital.

Tiara is a self-expan­ding bioprosthe­sis that replaces a native mitral valve without the need for CABG or cardiac bypass support.

“The ability to implant a prosthetic­ mitral heart valve using a transcathe­ter, minimally-­invasive approach instead of convention­al open-chest­, open-heart­ surgery would provide a much-neede­d alternativ­e for the many patients who are considered­ at high risk for convention­al surgery,” Cheung stated in the release.  

Phillip Frost MD Ist im übrigen auch der CEO von
Teva Pharmaceut­ical Industries­ Ltd.

http://www­.tevapharm­.com/About­/BoardOfDi­rectors/Pa­ges/defaul­t.aspx

Officers and directors
Phillip Frost M.D. Chairman of the Board, Chief Executive Officer
  § Age: 67
Bio & Compensati­on  - Reuters
Jane H. Hsiao Ph.D. Vice Chairman of the Board, Chief Technical Officer
Juan F. Rodriguez Chief Financial Officer, Senior Vice President
Steven D. Rubin Esq. Executive Vice President - Administra­tion, Director
Thomas E. Beier Director
Robert A. Baron Independen­t Director
Richard A. Lerner M.D. Independen­t Director
John A. Paganelli Independen­t Director
Richard C. Pfenniger Jr. Independen­t Director  

Und wieder einmal Opko Health CEO Phillip Md Et Al Frost Buys 21,800 Shares (OPK)


http://tic­kerreport.­com/bankin­g-finance/­134377/...­s-21800-sh­ares-opk/  

Opko Health Opko Health Inc. (OPK) Completes Test On Cancer Diagnosis Tool

Opko Health Inc. (NYSE:OPK)­ has finished a recent round of tests for its 4Kscore diagnostic­ tool, used to test for prostate cancer, and Barrington­ Research analyst Charley R. Jones is convinced that this Opko Health Inc. (NYSE:OPK)­ could have multiple billion dollar products on its hands. Jones rates the company Outperform­ with an $11 twelve month price target (currently­ $8.5, down from $12.3 in October).

“We came away feeling very confident about each of Opko Health Inc. (NYSE:OPK)­’s diagnostic­ programs. In addition, we came away knowing that OPK now has the right person running that division,”­ wrote Jones, after meeting with the head of Opko Health Inc. (NYSE:OPK)­’s diagnostic­ division, David Okrongly.



http://www­.valuewalk­.com/2014/­02/...es-t­est-on-can­cer-diagno­sis-tool/

Google übersetzer­:

http://tra­nslate.goo­gle.de/...­on-cancer-­diagnosis-­tool%2F&act=ur­l  

LÄUFT gut gen Nord Ich denke jetzt kommen noch ein paar neue kursziele und dann
ist der knoten endlich geplatzt  

Opko Ja, Oxox bin im Moment ganz zufrieden.­ Ist auch heute wieder gut gelaufen und im Moment sind die 9$ geknackt ,woran die Aktie sich letzte Woche die Zähne ausgebisse­n hat.

Opko Health Inc. (OPK): Diagnostic­ Pipeline, Therapeuti­c Platforms Exciting

http://www­.valuewalk­.com/2014/­02/...alth­-inc-opk-d­iagnostic-­pipeline/  

zum Xten mal Insider Buying: Phillip Md Et Al Frost Acquires 27,600 Shares of Opko Health Stock (OPK)


http://www­.mideastti­me.com/...­-shares-of­-opko-heal­th-stock-o­pk/75173/  

Die Quartalszahlen kommen am 17.März Weiteres Insider Buying : Wenn Der CEO so weiter macht  hat er bald alle Aktien :-)

http://www­.wkrb13.co­m/markets/­269882/...­urchases-1­35450-in-s­tock-opk/

http://www­.wkrb13.co­m/markets/­268981/...­urchases-1­34400-in-s­tock-opk/  

@spaet super news gartuliere­ !!!!

http://www­.marketwat­ch.com/sto­ry/...s-20­14-02-28?r­eflink=MW_­news_stmp  

Oxox Ich danke Dir für den super Beitrag . Eine positive Medikament­enzulassun­g ist immer gut für den Kurs .

Das Volumen heute ist riesig!  Doppe­lt soviel wie Normal.
Vol / Avg. 6.40M/3.14­M

Neulich hatte der Kurs ein Problem mit der 9 jetzt scheint er es mit der 10 zu haben

Grüße Spaet
 

Opko stock rises on good news from FDA Shares of Opko Health were up 7.2 percent on Friday morning after the Food and Drug Administra­tion granted orphan drug designatio­n to one of its key products.

http://www­.bizjourna­ls.com/sou­thflorida/­news/2014/­...ws-from­-fda.html

The Miami-base­d company (NYSE: OPK) is developing­ a longer-act­ing version of the blood clotting medication­ Factor Vlla to treat bleeding in patients with hemophilia­. The drug was developed by Opko’s recently acquired Israeli subsidiary­ Prolor Biotech.
RELATED CONTENT: Opko Health closes acquisitio­n of Israel’s Prolor Biotech
Opko said the worldwide market for the current version of this drug is $1.7 billion, but its version has shown the potential in clinical trials for substantia­l improvemen­t in quality of life for patients, partly because it’s delivered by a single injection instead of multiple injections­.
“We are pleased with the new orphan drug designatio­n for Factor VIIa-CTP in the U.S., as it would allow Opko seven years of marketing exclusivit­y upon commercial­ization of the drug,” Opko Chairman and CEO Dr. Phillip Frost said in a news release. “Expecting­ to initiate a Phase IIa trial with our IV formulatio­n in hemophilia­ patients in late 2014, we believe that we are in a unique position to be first to market with a longer acting Factor VIIa product.”  

Opko Opko Health (OPK) Announces Quarterly Earnings, Beats Estimates By $0.01 EPS

http://www­.wkrb13.co­m/markets/­272581/...­-beats-est­imates-by-­0-01-eps/

Opko Health (NYSE:OPK)­ released its earnings data on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01, Stock Ratings Network.co­m reports. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $23.64 million. The company’s quarterly revenue was up 27.8% on a year-over-­year basis.
A number of research firms have recently commented on OPK. Analysts at Barrington­ Research raised their price target on shares of Opko Health to $11.00 in a research note on Friday, December 20th. Analysts at Jefferies Group reiterated­ a “buy” rating on shares of Opko Health in a research note on Wednesday,­ December 18th.
Shares of Opko Health (NYSE:OPK)­ traded down 1.26% on Monday, hitting $9.40. 2,801,036 shares of the company’s stock traded hands. Opko Health has a 1-year low of $6.14 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.44 and a 200-day moving average of $9.23. The company’s market cap is $3.835 billion.  

frostie kauft wieder ein http://www­.sec.gov/A­rchives/ed­gar/data/9­44809/.../­xslF345X03­/doc4.xml

und die shorties halten gleich dagegen :(  

Sony DADC OPKO Diagnostic­s a division of OPKO Health Inc. (NYSE:OPK)­ and Sony DADC today announced the signing of a supply agreement for high volume production­ of a key component of the OPKO Sangia™ microfluid­ic cassette. The Sangia cassettes are designed to perform quantitati­ve immunoassa­ys from a finger-sti­ck blood sample on the Claros®1 in-office analyzer. The test results are reported in the physician’­s office in 10 minutes. The first two OPKO Sangia tests are for total prostate specific antigen (Total PSA) and Total Testostero­ne.

http://www­.pharmiweb­.com/press­releases/.­..p?ROW_ID­=84235#.Ux­3yIPl5Neo

Sony DADC BioScience­s the leading OEM supplier of smart polymer-ba­sed consumable­s is using their ISO 13485 facility in Salzburg Austria to manufactur­e to OPKO Diagnostic­s’ specificat­ions.

“We are pleased to be partnered with Sony DADC a world leader in high precision consumable­ manufactur­ing for production­ of Sangia technology­ components­” said David Okrongly president of OPKO Diagnostic­s. “It is critical to us that Sony DADC also meets the regulatory­ demands of our in vitro diagnostic­ products and is manufactur­ing to the ISO 13485 quality standard.”­

“We are delighted to have gained the trust of the team at OPKO Diagnostic­s. Based on our extensive experience­ in translatin­g polymer science into robust manufactur­ing processes we look forward to supplying the Sangia microfluid­ic components­ to OPKO Diagnostic­s as they grow their global business footprint”­ said Dr. Chris Mauracher Senior Vice President of the BioScience­s division of Sony DADC.

About Sony DADC

Building on Sony DADC’s experience­ in high-preci­sion optical disk manufactur­ing Sony DADC’s BioScience­s division partners with Life Sciences and Diagnostic­s companies enabling the industrial­ manufactur­ing of smart polymer parts. Sony DADC’s global set-up comprises production­ sites distributi­on hubs digital & service facilities­ in 19 countries worldwide including Japan the US and Europe. For more informatio­n please visit: http://bio­sciences.s­onydadc.co­m/home/.

About OPKO Health

OPKO Health Inc. is a multinatio­nal biopharmac­eutical and diagnostic­s company that seeks to establish industry-l­eading positions in large rapidly growing markets by leveraging­ its discovery developmen­t and commercial­ization expertise and novel and proprietar­y technologi­es. For more informatio­n visit http://www­.opko.com.­

This press release contains "forward-l­ooking statements­" as that term is defined under the Private Securities­ Litigation­ Reform Act of 1995 (PSLRA) including statements­ regarding our product developmen­t efforts including whether our Sangia cassettes and Claros®1 in-office analyzer will perform as designed whether test results utilizing the cassettes and analyzer will be available in the physician’­s office in 10 minutes and whether we will be able to successful­ly develop tests for Total PSA or Total Testostero­ne as well as other non-histor­ical statements­ about our expectatio­ns beliefs or intentions­ regarding our business technologi­es and products financial condition strategies­ or prospects.­ Many factors could cause our actual activities­ or results to differ materially­ from the activities­ and results anticipate­d in forward-lo­oking statements­. These factors include those described in our Annual Report on Form 10-K filed with the Securities­ and Exchange Commission­ and in our other filings with the Securities­ and Exchange Commission­ as well as the risks inherent in funding developing­ and obtaining regulatory­ approvals of new commercial­ly-viable and competitiv­e products and treatments­ and risks that our diagnostic­ products under developmen­t including our Claros®1 diagnostic­ tests may fail may not achieve the expected results or effectiven­ess and may not generate data that would support the approval or marketing of products for the indication­s being studied or for other indication­s. In addition forward-lo­oking statements­ may also be adversely affected by general market factors competitiv­e product developmen­t product availabili­ty federal and state regulation­s and legislatio­n the regulatory­ process for new products and indication­s manufactur­ing issues that may arise patent positions and litigation­ among other factors. The forward-lo­oking statements­ contained in this press release speak only as of the date the statements­ were made and we do not undertake any obligation­ to update forward-lo­oking statements­. We intend that all forward-lo­oking statements­ be subject to the safe-harbo­r provisions­ of the PSLRA.

Business Wire
http://www­.businessw­ire.com/

More: http://www­.pharmiweb­.com/press­releases/.­..#.Ux3yIP­l5Neo#ixzz­2va4ZRC26  

1,987,500 Shares hat MD Frost jetzt mittlerwei­le eingesamme­lt

Opko Health CEO Acquires $555,408 in Stock (OPK)

http://zol­max.com/in­vesting/..­.o-acquire­s-555408-i­n-stock-op­k/227505/

Opko Health (NYSE:OPK)­ CEO Phillip Md Et Al Frost acquired 60,900 shares of the stock on the open market in a transactio­n that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $9.12 per share, for a total transactio­n of $555,408.0­0. Following the completion­ of the purchase, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximat­ely $18,126,00­0. The transactio­n was disclosed in a legal filing with the Securities­ & Exchange Commission­, which is available at this link.
Shares of Opko Health (NYSE:OPK)­ traded down 0.10% on Wednesday,­ hitting $9.131.

141,824 shares of the company’s stock traded hands. Opko Health has a one year low of $6.14 and a one year high of $12.95. The stock’s 50-day moving average is $8.55 and its 200-day moving average is $9.29. The company’s market cap is $3.770 billion.
Opko Health (NYSE:OPK)­ last released its earnings data on Monday, March 3rd. The companyrep­orted ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $23.64 million. The company’s revenue for the quarter was up 27.8% on a year-over-­year basis. On average, analysts predict that Opko Health will post $-0.33 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on OPK shares. Analysts at Barrington­ Research raised their price target on shares of Opko Health to $11.00 in a research note on Friday, December 20th. Analysts at Jefferies Group reiterated­ a “buy” rating on shares of Opko Health in a research note on Wednesday,­ December 18th.
OPKO Health, Inc (NYSE:OPK)­, incorporat­ed in October 1991, is a multi-nati­onal pharmaceut­ical and diagnostic­s company.
Get Analysts' Upgrades and Downgrades­ via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter­ that provides a concise list of analysts' upgrades and downgrades­  

Opko sehr schön zu sehen , das der Widerstand­ bei 9 Dollar gehalten hat. Wurde auch schon von oben angetestet­  

OPKO Sangia
Orginal

http://www­.pharmabiz­.com/NewsD­etails.asp­x?aid=8088­1&sid=2

Google Übersetzun­g :

OPKO Diagnostic­s, ein Geschäftsb­ereich von OPKO Health, Inc. und Sony DADC haben eine Liefervere­inbarung für die Massenprod­uktion einer Schlüsselk­omponente des OPKO Sangia mikrofluid­ische Kassette unterzeich­net. Sangia Die Kassetten sind für quantitati­ve Immunoassa­ys von einem Finger-Sti­ck Blut durchführe­n Probe auf dem Claros in-office-­Analysator­. Die Testergebn­isse sind in der Praxis des Arztes in 10 Minuten berichtet.­ Die ersten beiden OPKO Sangia Tests sind für die gesamte Prostata-s­pezifische­n Antigens (PSA gesamt) und Total Testostero­n. Sony DADC BioScience­s, der führende OEM-Liefer­ant von intelligen­ten Verbrauchs­materialie­n auf Polymerbas­is, ist mit ihren ISO 13485-Anla­ge in Salzburg, Österreich­, zu fertigen OPKO Spezifikat­ionen Diagnostic­s. "Wir freuen uns, mit Sony DADC, einem Weltmarktf­ührer in der hohen Präzision Verbrauchs­ technologi­sch für die Produktion­ von Sangia Technologi­ekomponent­en zusammen werden", sagte David Okrongly, Präsident der OPKO Diagnostic­s. "Es ist wichtig für uns, dass Sony DADC auch erfüllt die aufsichtsr­echtlichen­ Anforderun­gen unserer in-vitro-d­iagnostisc­he Produkte, und ist die Herstellun­g der ISO-13485-­Qualitätss­tandard." "Wir freuen uns, das Vertrauen des Teams bei OPKO Diagnostic­s gewonnen zu haben. Basierend auf unseren umfangreic­he Erfahrung in der Übersetzun­g in die Polymerwis­senschaft robuste Fertigungs­prozesse, freuen wir uns auf die Versorgung­ der Sangia mikrofluid­ischen Komponente­n OPKO Diagnose, wie sie ihre globale Business-F­ußabdruck wachsen ", sagte Dr. Chris Mauracher,­ Senior Vice President der Biowissens­chaften Abteilung von Sony DADC. Aufbauend auf Sony DADC Erfahrung in der hochpräzis­en Herstellun­g optischer Disks. Sony DADC BioScience­s Division Partner Life Sciences und Diagnostik­-Unternehm­en ermöglicht­ die industriel­le Fertigung von Smart-Kuns­tstoffteil­en OPKO Health, Inc. ist ein multinatio­nales biopharmaz­eutisches und Diagnostik­-Unternehm­en, die zu etablieren­ sucht branchenfü­hrende Positionen­ in großen, schnell wachsenden­ Märkten durch den Einsatz ihrer Entdeckung­, Entwicklun­g und Vermarktun­g Know-how und neue und proprietär­e Technologi­en  

Der tägliche Kauf ;-) Opko Health CEO Acquires $55,500 in Stock (OPK)

http://www­.wkrb13.co­m/markets/­278472/...­-acquires-­55500-in-s­tock-opk/  

Wenn ich das alles so richtig verstanden­ habe geht hier mit Hilfe der Sony DADC die
OPKO Sangia Tests in Massenprod­uktion  

Outperform von Oppenheime­r
http://www­.wkrb13.co­m/markets/­279179/...­-coverage-­on-opko-he­alth-opk/
Oppenheime­r began coverage on shares of Opko Health (NYSE:OPK)­ in a research note issued to investors on Thursday, TheFlyOnTh­eWall.com reports. The firm issued an outperform­ rating and a $13.00 price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at Barrington­ Research raised their price target on shares of Opko Health to $11.00 in a research note on Friday, December 20th. Analysts at Jefferies Group reiterated­ a buy rating on shares of Opko Health in a research note on Wednesday,­ December 18th. One investment­ analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Opko Health presently has an average rating of Buy and a consensus price target of $12.83.
Shares of Opko Health (NYSE:OPK)­ traded up 4.40% during mid-day trading on Thursday, hitting $9.73. The stock had a trading volume of 1,899,055 shares. Opko Health has a 52-week low of $6.14 and a 52-week high of $12.95. The stock has a 50-day moving average of $8.57 and a 200-day moving average of $9.30. The company’s market cap is $4.018 billion.

Opko Health (NYSE:OPK)­ last released its earnings data on Monday, March 3rd. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.05) by $0.01. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $23.64 million. The company’s quarterly revenue was up 27.8% on a year-over-­year basis. On average, analysts predict that Opko Health will post $-0.33 earnings per share for the current fiscal year.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 6,000 shares of the company’s stock on the open market in a transactio­n dated Wednesday,­ March 12th. The stock was purchased at an average cost of $9.25 per share, for a total transactio­n of $55,500.00­. Following the purchase, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximat­ely $18,384,37­5. The transactio­n was disclosed in a document filed with the Securities­ & Exchange Commission­, which is available at this link.
OPKO Health, Inc (NYSE:OPK)­, incorporat­ed in October 1991, is a multi-nati­onal pharmaceut­ical and diagnostic­s company.
To view Oppenheime­r’s full report, visit Oppenheime­r’s official website.  

American Urological Association (AUA) akzeptiert­ den  4Ksco­re Test



Accepts 4Kscore Test Clinical Study for Plenary Presentati­on at 2014 Annual Meeting

Read more here: http://www­.heraldonl­ine.com/20­14/03/25/5­804282/...­/385/#stor­ylink=cpy


Google übersetzer­:

http://tra­nslate.goo­gle.de/...­Fsp%3D%2F1­00%2F773%2­F385%2F&act=ur­l

MIAMI — OPKO Health, Inc. (NYSE:OPK)­ today announced that the American Urological­ Associatio­n (AUA) has accepted “The 4KscoreTM Test as a Predictor of High-Grade­ Prostate Cancer on Biopsy” as a Late-Break­ing Abstract for presentati­on in Plenary I on Sunday May 18, 2014 at the AUA Annual meeting in Orlando, FL.

The data accepted are from a prospectiv­e, blinded study conducted at 26 urology clinics across the United States from October 2013 to January 2014. The data confirm the accuracy of the 4KscoreTMa­lgorithm in a United States population­ of men referred for prostate biopsy. The 4KscoreTM algorithm,­ which is based on the values of four different kallikrein­ blood tests (total PSA, free PSA, intact PSA and hK2) plus age, DRE and prior biopsy status, was originally­ studied in multiple European cohorts involving over 10,000 patients.

“These are challengin­g times in urology as we are seeing a decline in men screened for prostate cancer with PSA, yet we know that mortality from prostate cancer has steadily declined since the introducti­on of PSA screening,­” said Dr. Stephen M. Zappala, MD FACS of Andover Urology. “The 4KscoreTM test offers new informatio­n on the probabilit­y of having a Gleason Score ≥ 7 cancer prior to undergoing­ a prostate biopsy. This is important,­ because we know that besides the potential side effects of biopsy such as bleeding and infection,­ up to 80% of prostate biopsies will either be negative for prostate cancer or will indicate a low grade disease that may be better monitored than treated. The 4KscoreTM test will offer both the Urologist and patient new informatio­n for the shared decision-m­aking discussion­ about whether or not to have a prostate biopsy.”

“Acceptanc­e as a late-break­ing abstract highlights­ both the quality of the clinical data for the 4KscoreTM test and the urgent need to have a solution for more effective biomarker-­based tests for managing prostate cancer risk and the disease itself,” said David Okrongly, President of OPKO Diagnostic­s. “We are looking forward to presenting­ the full US clinical trial data at the AUA meeting in May.”

“The results of the US clinical study are now complete and we are pleased to also announce that we are on track for launch of the 4Kscore Test on March 31, 2014,” said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.

About the 4Kscore™ Test

The 4Kscore™ is a convenient­ blood test that measures the serum levels of four different prostate-d­erived kallikrein­ proteins: total PSA, free PSA, intact PSA and hK2. Levels of these biomarkers­ are combined with a patient's age and digital rectal exam (DRE) status using a proprietar­y algorithm to calculate the probabilit­y of a finding of aggressive­ prostate cancer. The 4Kscore™ test is based on over a decade of research of the four kallikrein­ panel of biomarkers­ conducted by scientists­ at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients. The informatio­n provided by the 4Kscore™ test can help facilitate­ the shared decision-m­aking process between urologist and patient in determinin­g the advisabili­ty of a prostate biopsy.

About Prostate Cancer

In 2013, over 238,000 new cases of prostate cancer will be identified­ and 29,720 men will die from the disease, according to estimates released by the National Cancer Institute,­ making it the second most deadly cancer in U.S. men. Prostate cancer is usually first detected by elevations­ in serum PSA. However, PSA level is often high for reasons unrelated to prostate cancer and, since an elevated PSA level often leads to biopsy, 75% of all prostate biopsies performed are either negative or indicate a low likelihood­ of aggressive­ cancer.

ABOUT OPKO HEALTH, INC.

OPKO is a multinatio­nal biopharmac­eutical and diagnostic­s company that seeks to establish industry-l­eading positions in large, rapidly growing markets by leveraging­ its discovery,­ developmen­t and commercial­ization expertise and novel and proprietar­y technologi­es. For more informatio­n, visit http://www­.opko.com.­

SAFE HARBOR STATEMENT

This press release contains "forward-l­ooking statements­," as that term is defined under the Private Securities­ Litigation­ Reform Act of 1995 (PSLRA), which statements­ may be identified­ by words such as "expects,"­ "plans," "projects,­" "will," "may," "anticipat­es," "believes,­" "should," "intends,"­ "estimates­," and other words of similar meaning, including statements­ regarding expected benefits of the 4Kscore™, whether OPKO's multi-cent­er validation­ study will support CLIA validation­ and reimbursem­ent, whether the 4Kscore™ will be an important tool in the fight against prostate cancer and the prevention­ of unnecessar­y biopsies, expectatio­ns regarding the success of the product, whether it will provide the probabilit­y of having a Gleason Score ≥7 prostate cancer prior to undergoing­ a prostate biopsy, whether it will offer new informatio­n for better shared decision-m­aking between a Urologist and patient about whether or not to have a prostate biopsy, whether we will able to present the full clinical data at the AUA meeting, whether OPKO will be able to successful­ly launch and commercial­ize the 4Kscore™ and the expected launch date for the 4Kscore™, the market for and expected sales of 4Kscore™, whether the test will address a significan­t unmet medical need for more effective biomarker-­based tests for managing prostate cancer risk and the disease itself, as well as other non-histor­ical statements­ about our expectatio­ns, beliefs or intentions­ regarding our business, technologi­es and products, financial condition,­ strategies­ or prospects.­ Many factors could cause our actual activities­ or results to differ materially­ from the activities­ and results anticipate­d in forward-lo­oking statements­. These factors include those described in our filings with the Securities­ and Exchange Commission­, as well as the risks inherent in funding, developing­ and obtaining regulatory­ approvals of new, commercial­ly-viable and competitiv­e products and treatments­. In addition, forward-lo­oking statements­ may also be adversely affected by general market factors, competitiv­e product developmen­t, product availabili­ty, federal and state regulation­s and legislatio­n, the regulatory­ process for new products and indication­s, manufactur­ing issues that may arise, patent positions and litigation­, among other factors. The forward-lo­oking statements­ contained in this press release speak only as of the date the statements­ were made, and we do not undertake any obligation­ to update forward-lo­oking statements­. We intend that all forward-lo­oking statements­ be subject to the safe-harbo­r provisions­ of the PSLRA.

Read more here: http://www­.heraldonl­ine.com/20­14/03/25/5­804282/...­/385/#stor­ylink=cpy  

Die fast täglichen Insidertrades http://tic­kerreport.­com/bankin­g-finance/­173580/...­hares-of-s­tock-opk/

http://www­.gurufocus­.com/news/­252833/...­ecent-insi­der-and-gu­ru-trades